Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486)
The DOI matches its Crossref record.
Abstract
Brief Reports15 January 1991Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486)Aart-Jan van der Lely, MD, Karin Foeken, MD, Roos C. van der Mast, MD, Steven W. J. Lamberts, MDAart-Jan van der Lely, MD, Karin Foeken, MD, Roos C. van der Mast, MD, Steven W. J. Lamberts, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-2-143 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe progesterone-receptor antagonist, RU 486 (mifepristone), is also, at higher concentrations, an effective antagonist of glucocorticoid action in vitro and in vivo (1-3). In normal humans, RU 486 blocks glucocorticoid negative feedback at the hypothalamic-pituitary level, inducing a compensatory increase in plasma adrenocorticotropin (ACTH) and cortisol levels (4, 5). In previous studies, patients with the Cushing syndrome caused by ectopic ACTH secretion or by adrenocortical carcinomas who received therapy with RU 486 (5 to 22 mg/kg body weight per day) showed clinical improvement, and no compensatory increases in plasma ACTH or cortisol levels were noted, probably because of ongoing hypothalamic...References1. Philibert D, Deraedt R, and Teutsch G. RU 486: a potent antiglucocorticoid in vivo [Abstract]. International Congress of Pharmacology, Tokyo, Japan; 1981:1463. Google Scholar2. Proux-Ferland L, Cote J, Philibert D, and Deraedt R. Potent antiglucocorticoid activity of RU 38486 on ACTH secretion in vitro and in vivo in the rat [Abstract]. J Steroid Biochem. 1982;17:xvii. Google Scholar3. Lamberts S, Bons E, and Uitterlinden P. Studies on the glucocorticoid receptor blocking action of RU 38486 in cultured ACTH-secreting human pituitary tumor cells and normal rat pituitary cells. Acta Endocrinol (Copenh). 1985;109:64-9. CrossrefMedlineGoogle Scholar4. Bertagna X, Bertagna C, Luton J, Husson J, and Girard F. The new steroid analogue RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab. 1984;59:25-31. CrossrefMedlineGoogle Scholar5. Gaillard R, Poffet D, Diondel A, and Saurat J. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab. 1985;61:1009-14. CrossrefMedlineGoogle Scholar6. Bertagna X, Bertagna C, Laudat M, Husson J, Girard F, and Luton Z. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab. 1986;63:639-42. CrossrefMedlineGoogle Scholar7. Nieman L, Chrousos G, and Nisula B. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61:536-40. CrossrefMedlineGoogle Scholar8. Nieman L, Udelsman R, Loriaux D, and Chrousos C. Antiglucocorticoids: basic and clinical studies. In: D'Agata R, Chrousos GP, eds. Recent Advances in Adrenal Regulation and Function. New York: Raven Press; 1987:235-58. Google Scholar9. Haskett R. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry. 1985;142:911-6. CrossrefMedlineGoogle Scholar10. Laue L, Callucci W, Loriaux D, Udelsman R, and Chrousos G. The antiglucocorticoid and antiprogestin steroid RU 486: its glucocorticoid agonist effect is inadequate to prevent adrenal insufficiency in primates. J Clin Endocrinol Metab. 1988;67:602-6. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Aart-Jan van der Lely, MD; Karin Foeken, MD; Roos C. van der Mast, MD; Steven W. J. Lamberts, MDFrom Erasmus University, Rotterdam, The Netherlands. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGlucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterationsMifepristone's effects on depression- and anxiety-like behavior in rodentsEndokrine StörungenSex differences in the hypothalamic–pituitary–adrenal axis: An obstacle to antidepressant drug development?Glucocorticoid and Mineralocorticoid Receptors in the Brain: A Transcriptional PerspectiveManage psychiatric symptoms in Cushing's syndrome by controlling cortisol levels and usual psychiatric therapyMifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic DepressionPsychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and ManagementUpdate on medical treatment for Cushing's diseaseA Mixed Glucocorticoid/Mineralocorticoid Selective Modulator With Dominant Antagonism in the Male Rat BrainAnna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the hypothalamic–pituitary–adrenal (HPA) axis in the pathogenesis of psychotic major depressionTreatment of Cushing's disease: a mechanistic updateNext Generation Medical Therapy for Cushing's Syndrome—Can We Measure a Benefit?Hypothalamic
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
Korte, S. M., Koolhaas, J. M., Wingfield, J. C., & McEwen, B. S. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.08.009 · Cited by 1,097
Fleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
“…approach of blocking insidious effects of corticosteroid excess was first reported in studies where patients with Cushing’s syndrome were treated with RU486 (mifepristone), a nonpeptide antagonist at progesterone receptors and at GRs (Chu et al. 2001, Nieman et al. 1985, van der Lely et al. 1991).”
BackgroundThe stress cascade and schizophrenia: Etiology and onset
Corcoran, C., Walker, E., Huot, R., Mittal, V., Tessner, K., Kestler, L., & Malaspina, D. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007038 · Cited by 439
“…symptom in Cushing's disease (Saad et al. 1984; Gerson and Miclat 1985; Hirsch et al. 2000), and case reports indicate that there is a remission of psychosis in Cushing's disease with correction of the endogenous hypercortisolemia (Johnson 1975; van der Lely et al. 1991; Chu et al. 2001).”
Background
Metadata
- Authors
- van der Lely, A.-J., Foeken, K., van der Mast, R. C., & Lamberts, S. W. J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1991-01-15
- Volume
- 114
- Issue
- 2
- Pages
- 143-144
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1987840185
- Cited by
- 105
- References
- 0
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486). https://app.cochat.ai/papers/10.7326/0003-4819-114-2-143
- The paper
- van der Lely, A.-J., Foeken, K., van der Mast, R. C., & Lamberts, S. W. J. (1991). Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486). Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-114-2-143
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.